Nebenwirkungen · Sitagliptin Accord
Sitagliptin Accord 25 mg film-coated tablets Sitagliptin Accord 50 mg film-coated tablets Sitagliptin Accord 100 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-148074 · Präparat HOS-099826
TECOS cardiovascular safety study The trial evaluating cardiovascular outcomes with sitagliptin (TECOS) included 7,332 patients treated with sitagliptin, 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and < 50 mL/min/1.73 m2), and 7,339 patients treated with placebo in the intention-to-treat population. Both treatments were added to usual care targeting regional standards for HbA1c and cardiovascular (CV) risk factors. The overall incidence of serious adverse events in patients receiving sitagliptin was similar to that in patients receiving placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-27T15:33:00Z · SHA-256 bea58f9fde8e11591ed9625cec516482359c02eeb5f49a1055538124cd0defc2 · Passage 982c7124f1891d3113b3817dfe33d3d5750ce59e23d0fea86b177260e2d04c86 · Zeichen 5368–5935 im Abschnitt